The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 03, 2015

Filed:

May. 06, 2013
Applicant:

Gilead Biologics, Inc., Foster City, CA (US);

Inventors:

Victoria Smith, Burlingame, CA (US);

Scott Ogg, San Francisco, CA (US);

Peter Van Vlasselaer, Portola Valley, CA (US);

Vivian E. Barry, Foster City, CA (US);

Derek Marshall, Pacifica, CA (US);

Alison Kay Holzer, Redwood City, CA (US);

Hector Rodriguez, Brisbane, CA (US);

Miho Oyasu, San Mateo, CA (US);

Scott Alan McCauley, Brisbane, CA (US);

Carlos Aurelio Garcia, San Lorenzo, CA (US);

Donna Hiroko Tokuoka Biermann, San Mateo, CA (US);

Assignee:

Gilead Biologics, Inc., Foster City, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 39/385 (2006.01); G01N 33/574 (2006.01); C07K 16/40 (2006.01); A61K 45/06 (2006.01); C12Q 1/68 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57423 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/40 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57438 (2013.01); G01N 33/57484 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/30 (2013.01); C07K 2317/33 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); G01N 2333/90633 (2013.01);
Abstract

The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.


Find Patent Forward Citations

Loading…